NASDAQ$RNA

Atrium Therapeutics Inc · Q2 2024 earnings

Q2 2024 earnings ·

Briefing

RNA Q2 2024 — $2.0M revenue, 0.65 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q2 2024 results. Diluted EPS came in at $0.65. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.0M.
  • Diluted EPS: $0.65.
  • Filed on Form 10-Q (accession 0001599901-24-000142).

Headline financials

Total Revenue

$2.05M

Previous: $2.32M-11.7%
EPS

-$0.65

Previous: -$0.66+1.5%
Capital Expenditures

-$1.45M

Previous: -$2.44M+40.8%
Free Cash Flow

-$72.2M

Previous: -$49.5M-46.0%
Net Income

-$70.8M

Previous: -$47M-50.5%
Operating Income

-$82.6M

Previous: -$52.6M-57.0%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.05M

Q2 2024-11.7%vs Q2 2023
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro